JENNEREX BIOTHERAPEUTICS
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.
JENNEREX BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2003-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.jennerex.com
Total Employee:
11+
Status:
Active
Contact:
14155982600
Total Funding:
56.05 M USD
Technology used in webpage:
Domain Not Resolving Apache GoDaddy DNS Sectigo SSL Sectigo Domain SSL GoDaddy Premium DNS Bizland
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Oncolix
Oncolix is a clinical-stage bio-pharmaceutical company developing a therapeutic protein for the treatment of cancer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2007-01-01
Current Employees Featured
Georg Roth Head of Technical Operations @ Jennerex Biotherapeutics
Head of Technical Operations
Ursula Fritsch Vice President of Quality Assurance & Regulatory Affairs @ Jennerex Biotherapeutics
Vice President of Quality Assurance & Regulatory Affairs
John Bell Co-Founder & Chief Scientific Officer @ Jennerex Biotherapeutics
Co-Founder & Chief Scientific Officer
Founder
Investors List
Ottawa Regional Cancer Foundation
Ottawa Regional Cancer Foundation investment in Series C - Jennerex Biotherapeutics
More informations about "Jennerex Biotherapeutics"
Jennerex - Wikipedia
Jennerex Biotherapeutics, Inc. (now owned by SillaJen) was an American private biopharmaceutical company [1] [3] that developed the oncolytic viruses JX-594 [1] [4] and JX …See details»
Jennerex Biotherapeutics - Crunchbase Company …
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted …See details»
Jennerex | SILLAJEN
Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply to tumors, and by activating …See details»
Jennerex Biotherapeutics - 2025 Company Profile - Tracxn
Jennerex Biotherapeutics is an acquired company based in San Francisco (United States), founded in 2003 by David Kirn. It operates as a Develops Oncolytic viruses for cancer. …See details»
Organization | Jennerex Inc.
Organization Overview. First Clinical Trial. 2008 NCT00629759. First Marketed Drug. None First NDA Approval. None ... Jennerex Biotherapeutics | Jennerex Biotherapeutics (Jennerex, Inc.) …See details»
Jennerex, Inc. - San Francisco, USA - bionity.com
Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in …See details»
Jennerex Biotherapeutics - PitchBook
Jennerex Biotherapeutics General Information Description. Developer of oncolytic products intended to treat cancer. The company provides an engineered oncolytic virus that selectively targets and destroys cancer cells and targets the …See details»
Jennerex Biotherapeutics - Products, Competitors, Financials, …
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. Use …See details»
Jennerex Biotherapeutics Inc - Company Profile and News
Company profile page for Jennerex Biotherapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
SillaJen Announces Agreement to Acquire Jennerex, Inc.
Dec 2, 2013 Jennerex is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life …See details»
EIN 26-1730046 - Jennerex, Inc., San Francisco, California
Jennerex, Inc. is a corporation in San Francisco, California. The employer identification number (EIN) for Jennerex, Inc. is 261730046. EIN for organizations is sometimes also referred to as …See details»
Korea's SillaJen to acquire Jennerex in up to $150 million deal
Nov 27, 2013 To this end, SillaJen says it is actively collaborating with Jennerex and its global partners on transition planning, including finalizing a robust clinical development plan. It …See details»
Jennerex Biotherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Jennerex and Transgene Enter Into an Exclusive Partnership for the
Sep 8, 2010 /CNW/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic...See details»
jennerex – The Virus Project
Organizations; Media Resources; About. THE VIRUS PROJECT; About the Site; Virus Project Team; Altru Institute; Newsletters; Open Source Journalism ... August 15, 2009 0. Jennerex …See details»
Jennerex Biotherapeutics | CipherBio
Explore Jennerex Biotherapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
What is Jennerex? Company Culture, Mission, Values
See what employees say it's like to work at Jennerex. Salaries, reviews, and more - all posted by employees working at Jennerex.See details»
Jennerex Completes $8.3 Million Series B Financing and Appoints …
Sep 10, 2008 Advertisement Jennerex also announces the appointment of Calvin Stiller, CM, O. ONT, MD, F.R.C.P. (C) to the Company's Board of Directors. Dr. Stiller is Chairman of the …See details»
Jennerex | 신라젠
Jennerex는 항암바이러스 분야에서 초창기 선구자였습니다. Jennerex 연구진에 의해 규명된 펙사벡의 작용기전은 펙사벡 감염에 의한 암세포 직접 살상, 암혈관 차단, 환자의 면역체계 …See details»
Jennerex Plucks $21.6M Private Placement; Is IPO Up Next?
May 24, 2013 Jennerex Biotherapeutics Inc. completed an insider-based $21.6 million private placement, capping a fruitful week that included the full enrollment of a Phase IIb study of …See details»